How is Nuclear Transfer Technology in Georgia? Interpretation of Reproductive Medicine Knowledge

Current Status and Compliance of Nuclear Transfer Technology in Georgia

A 38-year-old woman with an AMH level of 0.8 ng/mL, who had twice failed to have embryos transferred due to high fragmentation rates, asked during a consultation: "I saw online that egg nuclear transfer can be done in Georgia, placing a young donor's cell nucleus into my egg so that the child would have my DNA. Is this true?" The core of this question points to a special cell engineering technique in assisted reproduction—nuclear transfer (including pronuclear transfer, spindle transfer, polar body transfer, etc.). In Georgia, this technology is subject to local laws and the regulatory framework of reproductive medicine. Not all fertility centers can legally perform it, and the indications are strictly defined.

What is Nuclear Transfer Technology?

Nuclear transfer technology in the field of assisted reproduction usually refers to Mitochondrial Replacement Therapy (MRT) or oocyte nuclear replacement. The goal is to transfer the nucleus (carrying the main genetic material) of a woman's own egg into a donor's enucleated egg, thereby obtaining an egg with the woman's own nuclear DNA but mitochondrial DNA from the donor. This is mainly used for two types of situations:

• Preventing the transmission of maternal mitochondrial genetic diseases (such as Leigh syndrome, MELAS, etc.)
• Addressing issues like recurrent poor embryo development, high embryo fragmentation rates, and low blastocyst rates caused by poor egg cytoplasm quality

Is Nuclear Transfer Legally Permitted in Georgia?

Georgia's assisted reproductive laws are relatively liberal, allowing surrogacy and third-party donation, but there are clear restrictions on embryo manipulation and gene editing. As of 2025, Georgia has not officially approved mitochondrial replacement therapy for reproductive purposes. Some private fertility centers may perform similar operations under the guise of "egg activation" or "cytoplasmic transfer," but they lack official supervision and long-term follow-up data. Countries where nuclear transfer is legally performed currently include the UK (legal but requires strict approval), the USA (regulated by the FDA, only allowed for research applications, not commercial promotion), and Ukraine (some centers claim to perform it, but it's in a legal gray area). Georgia's situation is similar to Ukraine's, where it is not explicitly prohibited by law but lacks specific licensing.

How Do Doctors View Nuclear Transfer Technology in Georgia?

Professional judgments from reproductive doctors typically include the following points:

• High Technical Complexity: Nuclear transfer requires micromanipulation, synchronization of cell cycles, and avoidance of DNA damage, demanding extremely high standards of embryology lab hardware and personnel experience. The quality of embryology labs in most Georgian fertility centers varies greatly, and very few institutions can stably perform nuclear transfer.
• Lack of Success Rate Data: Even in clinical studies registered with the US FDA, data on embryo chromosomal abnormality rates, miscarriage rates, and long-term health outcomes of newborns after MRT are still insufficient. No authoritative institution in Georgia has published statistical data on live birth rates after nuclear transfer.
• Ethical Risks: Nuclear transfer involves third-party mitochondrial DNA, meaning the child will have genetic material from three individuals. Although the nuclear DNA comes from the parents, mitochondria are associated with the offspring's metabolism, intelligence, etc. Georgia lacks a corresponding genetic counseling and ethics committee review system.
• More Mature Alternatives: For recurrent poor embryo development due to poor egg quality, the first-line clinical recommendation is to use donor eggs (which can ensure high-potential embryos) or employ techniques like time-lapse embryo culture and assisted hatching, rather than directly resorting to nuclear transfer.

Differences in Applicability by Age Group

Easily Overlooked Detail: The "Homology" Issue of Mitochondrial DNA

Even after a successful nuclear transfer, the mitochondrial DNA of the donor egg may have genetic differences (haplotype differences) from the patient's own. Some mitochondrial haplotypes are weakly associated with neurological diseases and metabolic syndrome. Although the probability is low, mitochondrial haplotype matching should be considered when selecting donor eggs. Most centers in Georgia do not perform this test; patients need to request it actively and bear the additional cost.

Common Pitfalls: The Gap Between Promotion and Reality

• False Guarantees: Some centers claim that "the child from nuclear transfer will completely have your DNA," but in reality, the mitochondrial DNA comes from the donor. The offspring may be influenced by the donor's mitochondria in terms of blood type, immune function, etc., and it is not 100% inherited from the mother.
• Legal Identity Issues: If a child is born after nuclear transfer, the source of their mitochondrial DNA may not match conventional paternity tests. This could lead to legal obstacles when applying for birth certificates and nationality in Georgia. There have been cases of Russian couples who, after undergoing nuclear transfer in Ukraine, faced registration denial by household registration authorities upon returning home.
• Hidden Costs: The cost of nuclear transfer procedures is usually 3-5 times higher than conventional IVF. Additionally, donor eggs need to be purchased separately (if using cytoplasmic transfer techniques, eggs may need to be bought as carriers), potentially bringing the total cost to $20,000-$30,000.

Actual Process and Timeline

If you decide to attempt nuclear transfer in Georgia (assuming a facility claims to perform it), the typical process includes:

1. Preparatory Tests (1-2 weeks): Chromosomal karyotyping for both partners, whole genome sequencing (to confirm mitochondrial mutation points), infectious disease screening, AMH, vaginal ultrasound, semen analysis.
2. Finding an Egg Source (1-3 months): Matching donor eggs (needs to be as consistent as possible with the patient's blood type and mitochondrial haplotype).
3. Ovarian Stimulation and Egg Retrieval: The patient undergoes ovarian stimulation and egg retrieval, while the donor also undergoes egg retrieval.
4. Nuclear Transfer Procedure (1 day): Under a microscope, the nucleus (or spindle) is aspirated from the patient's egg and injected into the enucleated donor egg, followed by electrofusion or chemical fusion.
5. Embryo Culture and PGT (5-7 days): After reaching the blastocyst stage, a biopsy is performed for chromosomal aneuploidy screening (PGT-A) and mitochondrial DNA copy number testing.
6. Transfer and Luteal Support: Selecting a normal karyotype embryo for transfer.

Cost Influencing Factors

In Georgia, the cost of nuclear transfer technology is mainly composed of the following parts:

• Micromanipulation fee: approximately $3,000 - $5,000
• Donor egg fee: $2,000 - $5,000 (depending on the donor's education, appearance, etc.)
• PGT-A testing: $1,500 - $2,500 per embryo
• Medication costs: approximately $1,500 - $3,000
• Number of cycles: The success rate per transfer is about 15-25%, and most patients require 2-3 egg retrievals, with total costs potentially exceeding $15,000

Frequently Asked Questions

Q: Will a child conceived through nuclear transfer in Georgia inherit mitochondrial diseases?
A: If the procedure is successful, the proportion of the patient's own abnormal mitochondrial DNA should be less than 1% (usually the standard), theoretically avoiding the disease. However, a small number of residual mutant mitochondria may be enriched in the embryo, leading to symptom recurrence. Therefore, mitochondrial gene testing of the embryo is necessary, and regular blood tests are required after birth.

Q: Can nuclear transfer technology cause abnormalities in the offspring?
A: Animal experiments and limited human studies have not found a significantly increased risk, but there is a possibility of epigenetic modification changes. The first nuclear transfer baby in the US, born in 2015, is now nearly 10 years old with no reported significant abnormalities, but the sample size is extremely small and cannot be generalized to all cases.

Q: If I don't have a mitochondrial disease, but just have poor egg quality, can I undergo nuclear transfer?
A: This is considered "off-label" use and is not recommended by regulatory bodies. The greater risk is that if the patient's own egg nuclear DNA already has age-related double-strand breaks, nuclear transfer cannot repair them and may instead increase chromosomal abnormalities due to procedural damage. The priority clinical options are egg donation, assisted hatching, time-lapse culture, etc.

Observations from a Practitioner

As a medical coordinator with over ten years of experience in the assisted reproduction field, I have encountered many clients who consulted about nuclear transfer in Georgia. In reality, less than 5% truly meet the indications for nuclear transfer (carriers of mitochondrial genetic diseases). The rest are mostly older couples or those with repeated failures who wish to preserve their own genetic material. For these individuals, I usually recommend first trying three standard IVF cycles combined with time-lapse embryo imaging. If still unsuccessful, then consider egg donation. The promise of nuclear transfer sounds appealing, but the current technical environment and legal safeguards in Georgia cannot compare with those in the UK or the US. Blindly attempting it may result in high costs without achieving the desired outcome.

Risk Reminders

• There are no publicly available nationwide successful case data for nuclear transfer operations in Georgia. Patients must assess the risk of information asymmetry themselves.
• The chromosomal abnormality rate of embryos after the procedure may be higher than that of conventional IVF (due to micromanipulation induction). PGT-A testing should be considered mandatory.
• Regarding legal safety, it is recommended to sign a clear surgical informed consent form and consult with a local lawyer about the risks of household registration and nationality recognition for the child after birth.
• Uncontrolled amplification of residual maternal mitochondrial DNA is one of the core risks. It is essential to confirm that the mitochondrial copy number ratio is below an acceptable threshold through next-generation sequencing before embryo transfer.

In summary, there is a genuine demand for nuclear transfer technology in Georgia, but very few people meet the criteria. It faces high legal barriers, significant costs, and insufficient long-term follow-up data. Patients should first complete comprehensive genetic counseling to determine if it is the only feasible option, and then make a decision based on their own condition, age, and budget.